hotspot -WSS

hotspot

author：leisure time 2025-09-03 11:42:41 - browse：164

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

WSS

California man arrested in connection with serial murders of Mexican strip club workers

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

As AI in medicine takes off, can 'human in the loop' prevent harm?

FDA approves Leqembi, a milestone in Alzheimer’s treatment

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

entertainment

hotspot

hotspot

Virginia high school admissions case could be legal follow

With fresh data, a dynamic duo powers Eli Lilly to new heights

Peter Hotez and the public health issue of online harassment

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Dobbs anniversary: the lost opportunity of abortion as health care

UPS workers' union leader explains what's at stake as strike edges closer

Jerome Adams on the need for new antivirals for Covid

Drinking water from half of US faucets contains PFAS: Study

Sports medicine is finally prioritizing gender equality

Trump seeks lengthy delay of classified docs trial, citing upcoming election

hotspot

Rare Northern Lights show in US this week: Where and how to see it

Ebola: Gilead Sciences antiviral shows promise as new treatment

FDA approves Leqembi, a milestone in Alzheimer’s treatment

UCLA team creates talking throat patch for voice disorders

Another man arrested in connection with shooting at Kansas nightclub

First U.S. drug developed to treat liver disease MASH is approved

Wikipedia

hotspot

hotspot

hotspot